Inactive Ingredient Search for Approved Drug Products

About this Database | Back to Search Page

Guidances | CFR

You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with O

	Quarter	Inactive Ingredient	Route of Administration	Dosage Form	Maximum Potency per unit dose	Maximum Daily Exposure	Status
138115	Q3 2022	OPADRY 03B82849 YELLOW	ORAL	TABLET	20.00 mg	40mg	Deletion
138116	Q3 2022	OPASPRAY K-1-2275 YELLOW	ORAL	TABLET	NA		Deletion
138117	Q3 2022	OPASPRAY K-1-3197 GREEN	ORAL	TABLET	1.12 mg		Deletion
138331	Q2 2022	OPADRY II 85F34610 PINK	ORAL	TABLET	4.00 mg		MDE Replacement
138332	Q3 2022	OPADRY II 85F34610 PINK	ORAL	TABLET		8mg	MDE Replacement
138333	Q2 2022	OPADRY II 85F48105	ORAL	TABLET	1.50 mg		MDE Replacement
138334	Q3 2022	OPADRY II 85F48105	ORAL	TABLET		32mg	MDE Replacement
138335	Q2 2022	OPADRY II YS-1-19025A CLEAR	ORAL	GRANULE, FOR SUSPENSION	7.08 mg		MDE Replacement
138336	Q3 2022	OPADRY II YS-1-19025A CLEAR	ORAL	GRANULE, FOR SUSPENSION		14mg	MDE Replacement
138337	Q2 2022	OPADRY OY-7300 WHITE	ORAL	TABLET	35.00 mg		MDE Replacement
138338	Q3 2022	OPADRY OY-7300 WHITE	ORAL	TABLET		95mg	MDE Replacement
138339	Q2 2022	OPADRY YELLOW	ORAL	TABLET, EXTENDED RELEASE	13.20 mg		MDE Replacement
138340	Q3 2022	OPADRY YELLOW	ORAL	TABLET, EXTENDED RELEASE		47mg	MDE Replacement
138341	Q2 2022	OPADRY YS-1-14129 PINK	ORAL	CAPSULE, EXTENDED RELEASE	9.00 mg		MDE Replacement
138342	Q3 2022	OPADRY YS-1-14129 PINK	ORAL	CAPSULE, EXTENDED RELEASE		9mg	MDE Replacement
138343	Q2 2022	OPADRY YS-3-7413 CLEAR	ORAL	TABLET, EXTENDED RELEASE	4.00 mg		MDE Replacement
138344	Q3 2022	OPADRY YS-3-7413 CLEAR	ORAL	TABLET, EXTENDED RELEASE		35mg	MDE Replacement

 

 

FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly

Data Through: July 1, 2022
Database Last Updated: July 18, 2022